162 related articles for article (PubMed ID: 27702934)
1. Efficacy of extracorporeal ultrafiltration in patients with diuretic-resistant heart failure.
Nakazawa N; Nakabayashi K; Oka T
BMJ Case Rep; 2016 Oct; 2016():. PubMed ID: 27702934
[TBL] [Abstract][Full Text] [Related]
2. Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
Takada T; Masaki T; Hoshiyama A; Toki T; Kamata Y; Shichiri M
Nephrology (Carlton); 2018 Sep; 23(9):883-886. PubMed ID: 29665203
[TBL] [Abstract][Full Text] [Related]
3. [Alternatives to conventional diuretic therapy in heart failure].
Morales-Rull JL; Trullàs JC; Formiga F
Med Clin (Barc); 2014 Mar; 142 Suppl 1():42-8. PubMed ID: 24930083
[TBL] [Abstract][Full Text] [Related]
4. [Tolvaptan in a pediatric cardiorenal syndrome: What is its role?].
Tejero Hernández MA; García Martínez E; Arroyo Marin MJ; Gómez Guzmán E
Arch Argent Pediatr; 2018 Apr; 116(2):e279-e282. PubMed ID: 29557615
[TBL] [Abstract][Full Text] [Related]
5. [The peritoneal ultrafiltration in patients with cardio-renal disease].
Corciulo R; Corciulo S
G Ital Nefrol; 2017 Mar; 34(Suppl 69):86-103. PubMed ID: 28682031
[TBL] [Abstract][Full Text] [Related]
6. Extracorporeal ultrafiltration in heart failure and cardio-renal syndromes.
Costanzo MR; Cozzolino M; Aspromonte N; Mistrorigo F; Valle R; Ronco C
Semin Nephrol; 2012 Jan; 32(1):100-11. PubMed ID: 22365168
[TBL] [Abstract][Full Text] [Related]
7. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.
Felker GM; Mentz RJ; Adams KF; Cole RT; Egnaczyk GF; Patel CB; Fiuzat M; Gregory D; Wedge P; O'Connor CM; Udelson JE; Konstam MA
Circ Heart Fail; 2015 Sep; 8(5):997-1005. PubMed ID: 26374918
[TBL] [Abstract][Full Text] [Related]
8. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.
Imamura T; Kinugawa K
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784173
[TBL] [Abstract][Full Text] [Related]
9. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
[TBL] [Abstract][Full Text] [Related]
10. [Effect of tolvaptan on ascites due to malignancy].
Mitsuhashi N; Nemoto S; Satoh Y; Aoki Y; Teranaka R; Sasaki K; Shimazaki R; Ueda A; Nishino H; Akiyama T; Hosokawa I; Yoichi T; Kawamoto J; Kuboki S; Yoshitomi H; Kato A; Shimizu Y; Ohtsuka M; Shimizu H; Miyazaki M
Gan To Kagaku Ryoho; 2015 Feb; 42(2):201-5. PubMed ID: 25743139
[TBL] [Abstract][Full Text] [Related]
11. Preliminary report of tolvaptan treatment in Japanese patients with heart failure.
Semba H; Kinugawa K; Takeda N; Shiga T; Nishimura G; Inajima T; Uchino Y; Iwata H; Hasumi E; Abe H; Terada Y; Yonenaga A; Hirata Y; Nagai R
Int Heart J; 2012; 53(1):72-4. PubMed ID: 22398679
[TBL] [Abstract][Full Text] [Related]
12. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
[TBL] [Abstract][Full Text] [Related]
13. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
[TBL] [Abstract][Full Text] [Related]
14. Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention.
Masuda T; Murakami T; Igarashi Y; Okabe K; Kobayashi T; Takeda SI; Saito T; Sekiguchi C; Miyazawa Y; Akimoto T; Saito O; Muto S; Nagata D
Intern Med; 2016; 55(19):2759-2764. PubMed ID: 27725533
[TBL] [Abstract][Full Text] [Related]
15. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
Kadota M; Ise T; Yagi S; Iwase T; Akaike M; Ueno R; Kawabata Y; Hara T; Ogasawara K; Bando M; Bando S; Matsuura T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Sata M
Int Heart J; 2016 Jul; 57(4):461-5. PubMed ID: 27357439
[TBL] [Abstract][Full Text] [Related]
16. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
[TBL] [Abstract][Full Text] [Related]
17. Early introduction of tolvaptan after cardiac surgery: a renal sparing strategy in the light of the renal resistive index measured by ultrasound.
Kato TS; Ono S; Kajimoto K; Kuwaki K; Yamamoto T; Amano A
J Cardiothorac Surg; 2015 Nov; 10():143. PubMed ID: 26525900
[TBL] [Abstract][Full Text] [Related]
18. Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria.
Takagi K; Sato N; Ishihara S; Sone M; Tokuyama H; Nakama K; Omote T; Kikuchi A; Ishikawa M; Amitani K; Takahashi N; Maruyama Y; Imura H; Shimizu W
Heart Vessels; 2018 Apr; 33(4):413-420. PubMed ID: 29063302
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of tolvaptan in patients hospitalized for heart failure with refractory hyponatremia. Clinical experience in daily practice.
Salterain-Gonzalez N; Esteban-Fernández A; García-López M; Lavilla-Royo FJ; Gavira-Gómez JJ
Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):503-4. PubMed ID: 24776057
[No Abstract] [Full Text] [Related]
20. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
Matsue Y; Ter Maaten JM; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; van der Meer P; Damman K; Voors AA; Goldsmith SR
Clin Res Cardiol; 2017 Oct; 106(10):802-812. PubMed ID: 28540483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
